{"filing":{"accession_number":"0001104659-26-083559","cik":"0001133869","ticker":"CAPR","company_name":"CAPRICOR THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"capr-20260709x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1133869/000110465926083559/capr-20260709x8k.htm"},"events":[{"id":17929,"run_id":16082,"accession_number":"0001104659-26-083559","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Capricor entered into a material lease agreement for approximately 171,000 square feet at 9625 Towne Centre Drive, San Diego, to serve as its new headquarters with expanded manufacturing and R\u0026D facilities. The lease involves approximately $958,000 monthly base rent over a 138-month term with an 18-month rent abatement, representing a significant operational and financial commitment.","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16584,"accession_number":"0001104659-26-083559","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Capricor entered into a material lease agreement for approximately 171,000 square feet at 9625 Towne Centre Drive, San Diego, to serve as its new headquarters with expanded manufacturing and R\u0026D facilities. The lease involves approximately $958,000 monthly base rent over a 138-month term with an 18-month rent abatement, representing a significant operational and financial commitment. While this is disclosed under Item 1.01 (Material Definitive Agreement), it is fundamentally an operational/strategic real estate transaction rather than a traditional M\u0026A activity, debt issuance, or other specific financial event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:06:38.468097+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16585,"accession_number":"0001104659-26-083559","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"reasoning":"Item 2.03 is filed and incorporates Item 1.01 by reference, indicating creation of a direct financial obligation. While the specific details are not provided in this excerpt, Item 2.03 is the standard disclosure vehicle for debt issuance, credit facilities, and similar financial obligations. The incorporation of Item 1.01 suggests a material transaction, likely a debt or financing arrangement typical of biotech companies seeking capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:06:38.468097+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16584,"accession_number":"0001104659-26-083559","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Capricor entered into a material lease agreement for approximately 171,000 square feet at 9625 Towne Centre Drive, San Diego, to serve as its new headquarters with expanded manufacturing and R\u0026D facilities. The lease involves approximately $958,000 monthly base rent over a 138-month term with an 18-month rent abatement, representing a significant operational and financial commitment. While this is disclosed under Item 1.01 (Material Definitive Agreement), it is fundamentally an operational/strategic real estate transaction rather than a traditional M\u0026A activity, debt issuance, or other specific financial event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:06:38.468097+00:00","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-07-14"},{"id":16585,"accession_number":"0001104659-26-083559","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.65,"reasoning":"Item 2.03 is filed and incorporates Item 1.01 by reference, indicating creation of a direct financial obligation. While the specific details are not provided in this excerpt, Item 2.03 is the standard disclosure vehicle for debt issuance, credit facilities, and similar financial obligations. The incorporation of Item 1.01 suggests a material transaction, likely a debt or financing arrangement typical of biotech companies seeking capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T21:06:38.468097+00:00","company_name":"CAPRICOR THERAPEUTICS, INC.","ticker":"CAPR","filing_date":"2026-07-14"}]}